This study demonstrated that OTUD5 could inhibit the transformation of malignant phenotypes of A549 cells by inducing the expression of p53, suggesting that OTUD5 may be used as a potential therapeutic target for NSCLC treatment. This evidence concerns the gene TP53 and non-small cell lung carcinoma.